Polymer Capital Management HK LTD Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS

Posted by George Bondi on Aug 24th, 2026

Polymer Capital Management HK LTD bought a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 177,897 shares of the company’s stock, valued at approximately $14,105,000. Ionis Pharmaceuticals makes up about 0.7% of Polymer Capital Management HK LTD’s holdings, making the stock its 18th biggest holding. Polymer Capital Management HK LTD owned about 0.11% of Ionis Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Grandfield & Dodd LLC raised its position in shares of Ionis Pharmaceuticals by 0.4% in the fourth quarter. Grandfield & Dodd LLC now owns 37,821 shares of the company’s stock worth $2,992,000 after buying an additional 146 shares in the last quarter. Checchi Capital Advisers LLC lifted its position in Ionis Pharmaceuticals by 3.7% during the first quarter. Checchi Capital Advisers LLC now owns 4,429 shares of the company’s stock valued at $333,000 after purchasing an additional 157 shares during the last quarter. Prospera Financial Services Inc lifted its position in Ionis Pharmaceuticals by 3.9% during the fourth quarter. Prospera Financial Services Inc now owns 4,759 shares of the company’s stock valued at $376,000 after purchasing an additional 178 shares during the last quarter. MetLife Investment Management LLC grew its stake in Ionis Pharmaceuticals by 2.6% in the 4th quarter. MetLife Investment Management LLC now owns 9,674 shares of the company’s stock worth $765,000 after buying an additional 246 shares in the last quarter. Finally, Public Employees Retirement System of Ohio grew its stake in Ionis Pharmaceuticals by 0.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 48,545 shares of the company’s stock worth $3,176,000 after buying an additional 301 shares in the last quarter. 93.86% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. BMO Capital Markets began coverage on Ionis Pharmaceuticals in a research report on Wednesday, August 19th. They set a “market perform” rating and a $60.00 price objective on the stock. Royal Bank Of Canada dropped their target price on Ionis Pharmaceuticals from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Leerink Partners boosted their price target on shares of Ionis Pharmaceuticals from $122.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Barclays reduced their price objective on Ionis Pharmaceuticals from $115.00 to $90.00 and set an “overweight” rating on the stock in a research note on Friday, July 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Friday, July 17th. Seventeen equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.15.

Get Our Latest Report on IONS

Ionis Pharmaceuticals Stock Performance

IONS opened at $59.74 on Monday. The company has a quick ratio of 7.73, a current ratio of 7.89 and a debt-to-equity ratio of 3.07. Ionis Pharmaceuticals, Inc. has a 52 week low of $41.71 and a 52 week high of $86.74. The stock has a market cap of $9.93 billion, a PE ratio of -17.27 and a beta of 0.41. The business has a 50 day moving average of $64.20 and a 200-day moving average of $72.08.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($1.08) by $0.39. The company had revenue of $267.95 million for the quarter, compared to analysts’ expectations of $189.10 million. Ionis Pharmaceuticals had a negative return on equity of 111.08% and a negative net margin of 64.76%.The firm’s revenue for the quarter was down 40.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.70 earnings per share. Equities research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.57 earnings per share for the current fiscal year.

Insider Transactions at Ionis Pharmaceuticals

In other news, EVP Holly B. Kordasiewicz sold 362 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $84.30, for a total value of $30,516.60. Following the sale, the executive vice president directly owned 22,096 shares of the company’s stock, valued at $1,862,692.80. The trade was a 1.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Allene M. Diaz sold 10,111 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $85.42, for a total value of $863,681.62. Following the completion of the transaction, the director directly owned 3,811 shares of the company’s stock, valued at approximately $325,535.62. This represents a 72.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 233,163 shares of company stock worth $18,316,551. Company insiders own 1.81% of the company’s stock.

About Ionis Pharmaceuticals

(Free Report)

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.